-

Sol-Millennium Responds to FDA’s Warning Letter and Safety Communication

CHICAGO--(BUSINESS WIRE)--Sol-Millennium, manufacturer of medical devices, including syringes for medicine delivery and testing, issued a statement regarding March 19th update to the FDA’s Safety Communication (“Evaluating Plastic Syringes Made in China for Potential Device Failures”) and a Warning Letter to Sol-Millennium.

After multiple communications with the FDA, we are confident that all the issues can be resolved.

Since November 2023, Sol-Millennium has been providing reports of actions it has taken to address any findings identified in the Warning Letter. These are regulatory in nature.

The principal focus of the Warning Letter is on our 510(k) and whether our “combination” products (needle + syringe attached) constitute a significant change or modification in design that could significantly alter the safety and effectiveness of the devices. The 510(k) for our needle and the 510(k) for our syringe as separate items are not in question by the FDA. We are in the process of submitting applications for premarket clearance for the combination product to address this observation. For the needle and the syringe combination products, we offer them separately (unattached) under our own cleared Sol-Millenniums’ 510(k)s.

Since September 2023, the FDA has inspected approximately one third of Sol-Millennium’s inbound shipments into the United States, including multiple lab tests, and has had zero quality concerns.

Sol-Millennium has no relationship with Jiangsu Caina Medical Co Ltd, and Jiangsu Shenli Medical Production Co Ltd. These are the two manufacturers cited in the FDA’s Safety Communication Letter that the FDA recommends to “Immediately transition away from using plastic syringes manufactured” by these manufactures… “[because of] potential quality and performance issues”. No Sol-Millennium products are manufactured by either company.

Sol-Millennium puts product safety and reliability as its top priority. Our devices undergo rigorous design and development processes to ensure they meet globally recognized ISO standards including ISO 7886-1:2017, ISO 7886-2:2020, ISO 8537:2016, ISO 7864:2016, and ISO 9626:2016 for their medical device portfolio.

For more information, please contact Sol-Millennium at info@sol-m.com.

Sol-Millennium Medical Group is one of the world's largest manufacturers of needles and syringes that provided 2 billion needles and syringes in global pandemic response. It is vertically integrated with locations across the globe. Sol-Millennium's innovative technology enhances both clinician and patient experience. With an international sales team dedicated to delivering knowledge and outstanding customer service, Sol-Millennium’s mission is building a healthier tomorrow.

Sol-Millennium Medical Group


Release Summary
Sol-Millennium responds to FDA's Warning Letter and Safety Communication.
Release Versions

More News From Sol-Millennium Medical Group

Sol-Millennium® Celebrates Positive Feedback on Needle-Free Insulin Injection Device in Canada

CHICAGO--(BUSINESS WIRE)--Sol-Millennium® Medical Group, a leading manufacturer of medical devices, has launched an innovative needle-free injection device for insulin administration, receiving widespread praise in Canada. Designed to improve the lives of millions of people with diabetes, this breakthrough technology eliminates the discomfort and anxiety often associated with traditional needle-based injections. The device, InsuJet™, employs advanced jet injection technology to deliver precise...

Sol-Millennium® Launches Revolutionary Needle-Free Injection Device for Insulin Administration in Canada

CHICAGO--(BUSINESS WIRE)--Sol-Millennium® Medical Group, manufacturer of medical devices, including syringes for medication delivery and testing, is proud to announce the launch of InsuJet™ Needle-free Device, designed specifically for the administration of insulin for diabetic patients. This innovative technology promises to enhance the quality of life for millions of individuals living with diabetes by eliminating the discomfort associated with traditional needle-based injections. InsuJet™ Ne...

Sol-Millennium Follow-up Response to FDA Communication

CHICAGO--(BUSINESS WIRE)--The FDA issued a Safety Communication on November 30, 2023, stating concerns that certain plastic syringes made in China may not provide consistent and adequate quality or performance. The notice lists concerns over “leaks, breakage, and other problems after manufacturers made changes to the syringe dimensions.” Sol-Millennium has not incorporated any changes to the dimensions of its syringes. Sol-Millennium users can continue to trust that Sol-Millennium’s syringes wi...
Back to Newsroom